drugset
drugset / Trial / NCT06129175

UCMSCs as Treatment for Patients With Acute Ischemic Stroke (Stroke Neuroncell-EX)

NCT06129175 ↗

Phase 2/3 Recruiting 80 enrolled Cytopeutics Sdn. Bhd. National University of Malaysia · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective of this study is to evaluate the functional recovery based on Barthel index (BI) and modified Rankin Scale (mRS) while the secondary objectives are to assess the survival and re-admission rate as well as to investigate the inflammatory response in a subclinical study within 1 year of Neuroncell-EX infusion in participants with acute ischemic stroke.

Timeline

Start
2023-12-19
Primary completion
2026-11-30
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Neuroncell-EX Cell therapy 2e+06 cells/kg Intravenous

Indications

ischemic stroke